Combined hormone therapy and radiation therapy for locally advanced prostate cancer.

The combination of radiotherapy and androgen suppression with luteinizing hormone releasing hormone agonist has become a standard of care for locally advanced prostate cancer. Phase III randomized trials have shown that for locally advanced prostate cancer a 4-month complete androgen blockade initiated 2 months prior radiotherapy and stopped at the completion of radiotherapy increased overall survival in patients with Gleason score 2-6, meanwhile an adjuvant long term androgen suppression (2.5-3 years) improved significantly overall survival.